Headlines about Meridian Bioscience (NASDAQ:VIVO) have been trending somewhat positive this week, according to Accern Sentiment. Accern rates the sentiment of media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Meridian Bioscience earned a daily sentiment score of 0.13 on Accern’s scale. Accern also gave headlines about the company an impact score of 45.2370935859819 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Here are some of the news headlines that may have effected Accern’s rankings:

Shares of Meridian Bioscience (VIVO) traded up $0.70 during midday trading on Monday, reaching $14.25. The company had a trading volume of 882,300 shares, compared to its average volume of 321,604. Meridian Bioscience has a 1 year low of $10.75 and a 1 year high of $18.20. The company has a quick ratio of 4.04, a current ratio of 5.85 and a debt-to-equity ratio of 0.30. The firm has a market capitalization of $601.59, a PE ratio of 20.96 and a beta of 0.89.

Meridian Bioscience (NASDAQ:VIVO) last issued its quarterly earnings results on Thursday, November 9th. The company reported $0.15 EPS for the quarter, meeting the consensus estimate of $0.15. Meridian Bioscience had a return on equity of 13.62% and a net margin of 11.52%. The firm had revenue of $49.70 million during the quarter, compared to analysts’ expectations of $48.28 million. During the same period in the prior year, the firm posted $0.14 earnings per share. The business’s quarterly revenue was up 5.7% compared to the same quarter last year. sell-side analysts forecast that Meridian Bioscience will post 0.66 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, November 30th. Shareholders of record on Monday, November 20th were paid a $0.125 dividend. The ex-dividend date was Friday, November 17th. This represents a $0.50 annualized dividend and a yield of 3.51%. Meridian Bioscience’s dividend payout ratio is 98.04%.

Several research firms have recently weighed in on VIVO. Zacks Investment Research cut Meridian Bioscience from a “hold” rating to a “sell” rating in a research report on Tuesday, October 24th. Canaccord Genuity reaffirmed a “hold” rating and set a $14.00 price objective on shares of Meridian Bioscience in a research report on Friday, October 13th. Two equities research analysts have rated the stock with a sell rating and four have assigned a hold rating to the stock. The stock has an average rating of “Hold” and an average price target of $11.50.

ILLEGAL ACTIVITY WARNING: This article was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another domain, it was copied illegally and republished in violation of United States and international trademark and copyright law. The correct version of this article can be read at https://www.thecerbatgem.com/2017/12/18/meridian-bioscience-vivo-receives-news-sentiment-score-of-0-13.html.

About Meridian Bioscience

Meridian Bioscience, Inc is a life science company engaged in the development, manufacture, sale and distribution of diagnostic test kits for gastrointestinal, viral, respiratory and parasitic infectious diseases, and elevated blood lead levels, and the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/quantitative PCR (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers.

Insider Buying and Selling by Quarter for Meridian Bioscience (NASDAQ:VIVO)

Receive News & Stock Ratings for Meridian Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience and related stocks with our FREE daily email newsletter.